MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 41,100 shares, a decrease of 11.6% from the March 15th total of 46,500 shares. Based on an average daily volume of 99,400 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.4% of the company’s shares are short sold.
MiNK Therapeutics Stock Down 7.7 %
NASDAQ:INKT opened at $0.91 on Tuesday. The firm has a market capitalization of $31.52 million, a P/E ratio of -1.38 and a beta of 0.13. MiNK Therapeutics has a twelve month low of $0.75 and a twelve month high of $3.34. The company has a fifty day moving average of $0.96 and a 200-day moving average of $1.00.
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). On average, analysts anticipate that MiNK Therapeutics will post -0.59 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Separately, HC Wainwright dropped their price target on shares of MiNK Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, March 21st.
Read Our Latest Stock Analysis on INKT
About MiNK Therapeutics
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
See Also
- Five stocks we like better than MiNK Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- The Charles Schwab Company Can Hit New Highs
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.